Parmax Pharma has received 'In-Principle' approval from BSE for its planned preferential issue of securities.

This significant step allows the company to issue 3.14 Cr equity shares and 2.15 Cr warrants, each convertible into an equal number of equity shares.

The issue price for both shares and warrants is set at Rs. 36.50 each.

This approval is a crucial milestone for Parmax Pharma, enabling it to proceed with capital raising to support its operations and strategic initiatives.